Luminate Medical

Initial Investment: In May 2022, Elkstone led a €4.7 million funding round for Luminate Medical, joined by investors like SciFounders and Faber. 

Additional Funding: In December 2024, Elkstone participated in a $15 million Series A extension led by US VC Artis Ventures.

Strategic Support: Elkstone's involvement extends beyond financial backing, offering strategic guidance to bolster Luminate's growth and innovation in cancer care. 

Driven by their expertise in medical innovation and a personal commitment to improving patient care. The founders journey began with the development of innovative solutions to address chemotherapy-induced side effects, particularly hair loss. Through significant funding and strategic partnerships, Luminate has grown into a leading medtech startup dedicated to revolutionizing oncology treatments. Although early days it has already achieved significant success.